These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37230899)

  • 1. Diagnosis and Management of Fabry Disease in High-Risk Renal Disease Patients in Taiwan: A Single Center Study.
    Shih CY; You ZH; Tsai SF; Wu MJ; Yu TM; Chuang YW; Chen CH
    Transplant Proc; 2023 May; 55(4):788-791. PubMed ID: 37230899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of Fabry Disease Screening in Male Pre-End Stage Renal Disease Patients with Unknown Etiology Found Through the Platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center.
    Lin CJ; Chien YH; Lai TS; Shih HM; Chen YC; Pan CF; Chen HH; Hwu WL; Wu CJ
    Kidney Blood Press Res; 2018; 43(5):1636-1645. PubMed ID: 30380558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutations.
    Chien YH; Lee NC; Chiang SC; Desnick RJ; Hwu WL
    Mol Med; 2012 Jul; 18(1):780-4. PubMed ID: 22437327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation.
    Hsu TR; Hung SC; Chang FP; Yu WC; Sung SH; Hsu CL; Dzhagalov I; Yang CF; Chu TH; Lee HJ; Lu YH; Chang SK; Liao HC; Lin HY; Liao TC; Lee PC; Li HY; Yang AH; Ho HC; Chiang CC; Lin CY; Desnick RJ; Niu DM
    J Am Coll Cardiol; 2016 Dec; 68(23):2554-2563. PubMed ID: 27931613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
    Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
    Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and functional characterization of the first deep intronic GLA mutation (IVS4+1326C>T) causing renal variant of Fabry disease.
    Dai X; Zong X; Pan X; Lu W; Jiang GR; Lin F
    Orphanet J Rare Dis; 2022 Jun; 17(1):237. PubMed ID: 35725559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
    Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
    BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).
    Hwu WL; Chien YH; Lee NC; Chiang SC; Dobrovolny R; Huang AC; Yeh HY; Chao MC; Lin SJ; Kitagawa T; Desnick RJ; Hsu LW
    Hum Mutat; 2009 Oct; 30(10):1397-405. PubMed ID: 19621417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
    Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
    Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation.
    Okur I; Ezgu F; Biberoglu G; Tumer L; Erten Y; Isitman M; Eminoglu FT; Hasanoglu A
    Gene; 2013 Sep; 527(1):42-7. PubMed ID: 23756194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of Fabry Disease of patients in renal replacement therapy in a population from Lazio (Italy).
    Marrone G; Angelico R; Di Lauro M; Sargentini E; Manzia TM; Tisone G; Mitterhofer AP; Della Morte Canosci D; Tesauro M; Di Daniele N; Noce A
    Eur Rev Med Pharmacol Sci; 2023 Apr; 27(7):3134-3141. PubMed ID: 37070916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deciphering the diagnostic dilemma: A comprehensive review of the Taiwanese cardiac variant in Fabry disease.
    Hwu WL
    J Formos Med Assoc; 2024 Jul; 123(7):738-743. PubMed ID: 37833114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease?
    Chaves-Markman ÂV; Markman M; Calado EB; Pires RF; Santos-Veloso MAO; Pereira CMF; Lordsleem ABMDS; Lima SG; Markman Filho B; Oliveira DC
    Arq Bras Cardiol; 2019 Jul; 113(1):77-84. PubMed ID: 31291414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fabry's disease (alpha-galactosidase-A deficiency): physiopathology, clinical signs, and genetic aspects].
    Germain DP
    J Soc Biol; 2002; 196(2):161-73. PubMed ID: 12360745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease: Review and experience during newborn screening.
    Hsu TR; Niu DM
    Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Characterization and Pharmacological Evaluation of a Novel GLA Missense Mutation Found in a Severely Affected Fabry Disease Family.
    Varela P; Mastroianni Kirsztajn G; Ferrer H; Aranda C; Wallbach K; Ferreira da Mata G; Moura LA; Moreira SR; Mendes C; Curiati MA; Martins AM; Bosco Pesquero J
    Nephron; 2020; 144(3):147-155. PubMed ID: 31665721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Screening Test of Fabry Disease in Patients with Renal Replacement Therapy in the City of Modena].
    Alfano G; Ganda N; Cerami C; Mori G; Fontana F; Cappelli G
    G Ital Nefrol; 2018 Mar; 35(2):. PubMed ID: 29582965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry.
    Romani I; Sarti C; Nencini P; Pracucci G; Zedde M; Cianci V; Nucera A; Moller J; Orsucci D; Toni D; Palumbo P; Casella C; Pinto V; Barbarini L; Bella R; Scoditti U; Ragno M; Mezzapesa DM; Tassi R; Volpi G; Diomedi M; Bigliardi G; Cavallini AM; Chiti A; Ricci S; Cecconi E; Linoli G; Sacco S; Rasura M; Giordano A; Bonetti B; Melis M; Cariddi LP; Dossi RC; Grisendi I; Aguglia U; Di Ruzza MR; Melis M; Sbardella E; Vista M; Valenti R; Musolino RF; Passarella B; Direnzo V; Pennisi G; Genovese A; Di Marzio F; Sgobio R; Acampa M; Nannucci S; Dagostino F; Dell'Acqua ML; Cuzzoni MG; Picchioni A; Calchetti B; Notturno F; Di Lisi F; Forlivesi S; Delodovici ML; Buechner SC; Biagini S; Accavone D; Manna R; Morrone A; Inzitari D
    J Neurol Sci; 2024 Feb; 457():122905. PubMed ID: 38295534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic.
    Zemánek D; Januška J; Honěk T; Čurila K; Kubánek M; Šindelářová Š; Zahálková L; Klofáč P; Laštůvková E; Lichnerová E; Aiglová R; Lhotský J; Vondrák J; Dostálová G; Táborský M; Kasper D; Linhart A
    ESC Heart Fail; 2022 Dec; 9(6):4160-4166. PubMed ID: 36087038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.